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Objective and Background: Our objective was to determine the fetal in vivo
microRNA signature in hypoplastic lungs of human fetuses with severe iso-
lated congenital diaphragmatic hernia (CDH) and changes in tracheal and
amniotic fluid of fetuses undergoing fetoscopic endoluminal tracheal occlu-
sion (FETO) to reverse severe lung hypoplasia due to CDH.
Methods: We profiled microRNA expression in prenatal human lungs by mi-
croarray analysis. We then validated this signature with real-time quantitative
polymerase chain reaction in tracheal and amniotic fluid of CDH patients
undergoing FETO. We further explored the role of miR-200b using semi-
quantitative in situ hybridization and immunohistochemistry for TGF-β2 in
postnatal lung sections. We investigated miR-200b effects on TGF-β signaling
using a SMAD-luciferase reporter assay and Western blotting for phospho-
SMAD2/3 and ZEB-2 in cultures of human bronchial epithelial cells.
Results: CDH lungs display an increased expression of 2 microRNAs: miR-
200b and miR-10a as compared to control lungs. Fetuses undergoing FETO
display increased miR-200 expression in their tracheal fluid at the time of
balloon removal. Future survivors of FETO display significantly higher miR-
200 expression than those with a limited response. miR-200b was expressed
in bronchial epithelial cells and vascular endothelial cells. TGF-β2 expres-
sion was lower in CDH lungs. miR-200b inhibited TGF-β-induced SMAD
signaling in cultures of human bronchial epithelial cells.
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Conclusions: Human fetal hypoplastic CDH lungs have a specific miR-
200/miR-10a signature. Survival after FETO is associated with increased
miR-200 family expression. miR-200b overexpression in CDH lungs results
in decreased TGF-β/SMAD signaling.
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C ongenital diaphragmatic hernia (CDH) is a developmental de-fect of the diaphragm, allowing herniation of abdominal viscera
into the chest. It occurs in 1 in 2000 to 3000 live births.1 Although
postnatal treatment has become more standardized, substantial mor-
bidity and mortality result from the associated pulmonary hypoplasia
and abnormal vascular development of the newborn. A subset of fe-
tuses with liver herniation and a smaller lung size, represented by
an observed overexpected lung-to-head ratio (O/E LHR) under 25%,
has higher mortality and morbidity rates and, therefore, today are of-
fered in utero fetal surgery. Fetoscopic endoluminal tracheal occlusion
(FETO)2 prevents normal egress of airway fluid, which in turn induces
tissue stretch, acting as a signal for lung growth. To stimulate lung
maturation, it was proposed to reverse the occlusion already in utero
(plug-unplug sequence),3 which also clinically seems to improve sur-
vival and morbidity.4,5 These preliminary observations are now being
evaluated in a randomized controlled trial [http://www.totaltrial.eu,
NIH NCT00763737 (moderate hypoplasia) and NIH NCT01240057
(severe hypoplasia)].6
A lack of understanding of the molecular mechanisms under-
lying pulmonary hypoplasia in CDH hampers progress for potential
in utero therapies and case selection. Although about 10% of CDH
patients have chromosomal anomalies, a common genetic cause for
CDH is unknown.7 However, it is widely accepted that the diaphrag-
matic defect and pulmonary hypoplasia result from a shared develop-
mental insult.8,9 MicroRNAs (miRNAs) are small noncoding RNAs
that regulate gene expression through posttranscriptional silencing of
messenger RNAs.10 MicroRNAs are essential for normal organogen-
esis during embryonic development. For example, targeted deletion of
miR-1 to 2 leads to congenital heart defects in mice.11 Previous stud-
ies have identified differential miRNA expression between various
stages of lung development, but these studies did not provide much
functional information.12 Whether specific miRNAs play a role in the
pathogenesis of human congenital lung diseases remains unknown.
Isolated CDH is characterized by abnormal lung development. The
first objective of this study was to determine whether severe human
hypoplastic CDH lungs display specific microRNA expression. The
second objective was to determine if the obtained microRNA signa-
ture could be used as a biomarker, by evaluating its expression in
tracheal and amniotic fluid samples of CDH patients before and after
forced lung growth. The third objective was to determine how abnor-
mal miR-200b expression influences target gene expression. This is
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Annals of Surgery  Volume 00, Number 00, 2015 www.annalsofsurgery.com | 1
Pereira-Terra et al Annals of Surgery  Volume 00, Number 00, 2015
the first study to identify abnormal miR-200/miR10a expression in
hypoplastic CDH lungs and in response to forced lung growth. The
expression of these microRNAs in tracheal fluid can be used to dis-
tinguish survivors of FETO from nonsurvivors. We also demonstrate
that increased miR-200b expression results in decreased target gene
expression via decreased TGF-β/SMAD signaling.
MATERIALS AND METHODS
MicroRNA Screen of Lung Specimens
RNA Isolation
Erasmus MC-Sophia’s institutional review board approved the
study protocol, and all the experiments were performed adhering to
the relevant guidelines of the Research Ethics Board of the University
of Manitoba. Surrogates provided consent for the use of human tissues
and biofluids. We biopsied lungs from 3 fetuses with isolated and
severe CDH and 3 age-matched controls without lung disease (22,
22, and 25 weeks of gestation) undergoing termination or pregnancy.
Total RNA of these lung specimens was extracted using Trizol reagent
(Invitrogen Life Technologies, Carlsbad, CA).
MicroRNA Profiling
The expression profile of 319 human miRNAs was investigated
using a liquid-phase bead-based array according to the manufacturer’s
instructions. Five microgram of total RNA was biotinylated at the 3’
end using the FlexmiR MicroRNA labeling kit (Luminex, Austin,
TX). The labeled RNA was hybridized to locked nucleic acid (LNA)
capture probes. Each probe is bound to a fluorescently dyed xMAP
bead. After washes, the biotinylated miRNAs were detected by reac-
tion with streptavidin-phycoerythrin. The samples were analyzed on
a Luminex-200 instrument. The measured intensities were subtracted
from a background control reaction and normalized against a set of
ubiquitously expressed small nucleolar RNAs (snoRNA). Heat maps
and statistical analyses were generated with the Institute for Genomic
Research MultiExperiment Viewer.
Real-Time Quantitative Polymerase Chain Reaction
Validation of MicroRNA Profile
We used the miRCURY LNA PCR system according to
the manufacturer’s instructions (Exiqon, Vedbaek, Denmark). LNA
primer sets were purchased from Exiqon (Table 1). After reverse
transcribing of the isolated RNAs, we used the SYBR Green assay
(Bio-Rad, Hercules, CA) for real-time quantitative polymerase chain
reaction (RT-qPCR) amplification. We included 3 small RNA species
as endogenous controls (SNORD38B, 5S rRNA and U6 snRNA). Of
these, SNORD38B had the most stable expression between different
samples and was used to normalize the data.
Biomarker Screen of Biofluids (Amniotic and
Tracheal Fluids)
Clinical Evaluation
Ultrasound evaluation was performed less than 48 hours be-
fore FETO plug (further referred to as baseline, typically around
26–28 weeks) and less than 48 hours before balloon removal (typ-
ically around 34 weeks). The degree of pulmonary hypoplasia was
estimated using 2-dimentional ultrasound and was expressed as an
LHR as described before.13,14 The LHR is corrected for gestational
age by expressing the LHR of the index case as a proportion of
what is normally expected for a gestational age-matched normal
fetus (observed/expected: O/E LHR). The relative increase in O/E
LHR compared to the baseline value was expressed as follows: [(O/E
LHR unplug − O/E baseline)/O/E baseline] × 100%. In addition, a
functional status of the pulmonary circulation was evaluated using a
maternal hyperoxygenation test. The relative difference between pre-
and posthyperoxygenation values was expressed as deltaPI: [(baseline
PI − PIO2) / baseline PI] × 100%.15,16
RNA Isolation
Amniotic and tracheal fluid were collected at the time of bal-
loon insertion and its removal (n = 21). Amniotic fluid was retrieved
at first entry into the amniotic cavity; tracheal fluid was sampled be-
low the vocal cords, through the fetoscopic sheath, taking care not
to contaminate it by irrigation fluid. The Ethics Committee of the
UZ Leuven has approved the fetal treatment and prospective follow-
up program of patients with CDH, as well as the use of fetal fluid
specimens to improve prenatal prediction of outcomes. We selected
archived (−80◦C) sample pairs from 11 consecutive “responders”
(defined as having a marked increase in O/E LHR from baseline
and who were eventually surviving) and 10 “nonresponders” (ie,
poor or absent increase in lung size and eventually neonatal death17)
(Table 2).
Blinded to clinical outcome, total RNA was extracted for RT-
qPCR using the miRCURY RNA Isolation Kit for Biofluids (Exiqon).
For normalization of sample-to-sample variation, 1 μL of synthetic
Caenorhabditis elegans miRNA (cel-miR-39) was added to each de-
natured sample.18,19 Small RNAs were then enriched and purified
according to the manufacturer’s protocol.
TABLE 1. LNA Primer Sets (Exiqon) Used in RT-qPCR
LNA MicroRNA Primer Set Target Sequence Description
SNORD38B TCTCAGTGATGAAAACTTTGTCCAGTTCTGCTACTG
ACAGTAAGTGAAGATAAAGTGTGTCTGAGGAGA
endogenous control
5S rRNA (hsa) GTCTACGGCCATACCACCCTGAACGCGCCCGATCTCGTCTGAT
CTCGGAAGCTAAGCAGGGTCGGGCCTGGTTAGTACTTG
GATGGGAGACCGCCTGGGAATACCGGGTGCTGTAGGCTTT
endogenous control
U6 snRNA (hsa, mmu) GTGCTCGCTTCGGCAGCACATATACTAAAATTGGA
ACGATACAGAGAAGATTAGCATGGCCCCTGCGCAA
GGATGACACGCAAATTCGTGAAGCGTTCCATATTTTT
endogenous control
hsa-miR-10a UACCCUGUAGAUCCGAAUUUGUG tested microRNA
hsa-miR-27a UUCACAGUGGCUAAGUUCCGC tested microRNA
hsa-miR-195 CCAAUAUUGGCUGUGCUGCUCC tested microRNA
hsa-let-7a CUAUACAAUCUACUGUCUUUC tested microRNA
hsa-miR-1 UGGAAUGUAAAGAAGUAUGUAU tested microRNA
hsa-miR-200b UAAUACUGCCUGGUAAUGAUGA tested microRNA
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Real-Time Quantitative Polymerase Chain Reaction
To optimize RT-qPCR performance, we did a dilution curve to
determine what input volume affected RT-qPCR performance. On the
basis of the outcome, 4μL of small RNAs from the biofluids samples
were reverse transcribed using the miRCURY LNA Universal RT mi-
croRNA PCR protocol (Exiqon) in a total reaction volume of 10μL.
The cDNA was diluted 1:40 μL in nuclease free water to be used
as a PCR template. PCR reactions for quantification of miR-200a,
miR-200b, miR-200c, miR-141, miR-429, miR-10a, and cell-miR-39
were performed in triplicate and 20μl was used as the reaction vol-
ume. The RT-qPCR reactions were performed using an ABI 7500
Real-Time PCR System with the following cycling conditions: 95◦C
for 10 minutes, followed by 45 cycles of 95◦C for 10 seconds and
60◦C for 1 minute. The cycle threshold (Ct) values were calculated
with ABI 7500 v1.4.0 software. The target microRNAs sequences of
the LNA mix primers are summarized in Table 3.
Calculation of miRNA Expression
The average expression levels of amniotic and tracheal fluid
miRNAs were normalized against cel-miR-3918,20,21 using the 2−Ct
method. Differences between the groups are presented as Ct, indi-
cating the difference between the Ct value of the miRNA of interest
and the Ct value of the normalizer miRNA. To ensure consistent
measurements and reproducibility throughout all assays, for each
PCR amplification reaction, one of the RNA samples was loaded
in triplicate in all the plates, as internal control to account for any
plate-to-plate variation, and the results from each plate were also nor-
malized against an internal normalization control. The expression lev-
els of microRNAs were normalized with the C. Elegans cel-miR-39
Spike-in kit.
In Situ Hybridization and Immunohistochemistry
We obtained postmortem neonatal lung tissues from 3 post-
natal CDH cases and 3 age-matched controls, without lung disease
(35, 37, and 40 weeks of gestation). All cases died within 1 hour
after birth. In situ hybridization was carried out on 5 μm sections
of formalin-fixed tissue as previously described.22 Our protocol was
first validated with an LNA control probe against U6 snRNA. A
scramble-miR probe was used as a negative control and did not pro-
duce a signal. In situ hybridization with a probe against miR-10a
TABLE 2. Demographic Information for CDH Fetuses Undergoing FETO
Baseline Characteristics of the Embryos
Characteristics Responders (n = 11) Nonresponders (n = 10) P
O/E LHR at first evaluation (%) 22.5 (23.6–17.5) 21.6 (24.0–15.9) 0.87
Liver herniated 10 (91%) 9 (100%) 1.00
Fetal gender (male/female) 7 (m)/4 (f) 4 (m)/5 (f) 0.65
FETO Pregnancy Data and Neonatal Outcome
FETO Data/Outcome Responders (n = 11) Nonresponders (n = 10) P
Gestational age at plug (wk) 28.1 (28.7–27.1) 27.9 (29.1–27.0) 0.84
Gestational Age at unplug (wk) 34.0 (34.1–33.4) 34 (34.5–33.9) 0.36
Occlusion days 39 (49–35) 43 (50–34) 0.64
Relative increase in O/E LHR 161.7 (252.4–140.8) 29.8 (10.4–50.2) <0.0001
Interval removal-delivery <24 h 1 (9%) 0 (0%) 1.00
PPROM 5 (45%) 3 (33%) 0.67
Gestational Age at PPROM (wk) 35.0 (35.9–32.6) 35.4 (36.6–29.3) 1.00
Gestational Age at delivery (wk) 37.0 (38.0–35.0) 38.0 (38.4–36.4) 0.25
Birth weight (g) 2780 (3180–2160) 3195 (3278–2650) 0.30
Oxygen at day 28 6 (55%) NA
NICU days 45 (61–30) NA
Day of neonatal death NA 1 (2–0)
All median (IQR) or n (%).
NA indicates not applicable. NICU indicates neonatal intensive care unit; PPROM, preterm premature rupture of membranes.
TABLE 3. MicroRNA Target Sequences for RT-qPCR and LNA Probes (Exiqon) Used for In Situ Hybridization
Target MicroRNA Sequence
hsa-miR-200a-3p UAACACUGUCUGGUAACGAUGU
hsa-miR-200b-3p UAAUACUGCCUGGUAAUGAUGA
hsa-miR-200c-3p UAAUACUGCCGGGUAAUGAUGGA
hsa-miR-141-3p UAACACUGUCUGGUAAAGAUGG
hsa-miR-429 UAAUACUGUCUGGUAAAACCGU
hsa-miR-10a-5p UACCCUGUAGAUCCGAAUUUGUG
cel-miR-39-3p UCACCGGGUGUAAAUCAGCUUG
Probe Sequence Concentration Hybridization Temperature
hsa-miR-200b TCATCATTACCAGGCAGTATTA 100 nM 52◦C
hsa-miR-10a CACAAATTCGGATCTACAGGGTA 100 nM 53◦C
scramble-miR GTGTAACACGTCTATACGCCCA 100 nM 57◦C
U6, positive control CACGAATTTGCGTGTCATCCTT 0.1 nM 54◦C
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produced a very weak signal in postnatal lung tissues. MicroRNA
species were hybridized with double-digoxigenin-labeled LNA
probes (Exiqon) for 1 hour (Table 3). We detected the hybridized
probes with an alkaline phosphatase–conjugated antidigoxigenin an-
tibody (1:500) (Roche, Mannheim, Germany). Sections were im-
munostained with 1-step NBT/BCIP solution, containing 1 mM lev-
amisole (Thermo Scientific, Rockford, IL). The slides were coun-
terstained with methyl green (Sigma-Aldrich, St Louis, MO). We
performed immunohistochemistry on neonatal lung tissue using an
anti-TGF-β2 antibody (1:100) (Abcam, Cambridge, MA) as previ-
ously described.23
Microscopy and Image Analysis
Digital microscopy was performed with the ScanScope CS
system (Aperio, Vista, CA). Semiquantitative measurements of the
in situ hybridization studies were obtained as follows. Images up to
200× magnification were obtained and analyzed using ImageScope
software (http://www.aperio.com). The entire area of each lung sec-
tion was digitally mapped using the colocalization algorithm. The
blue and green stainings were first calibrated with the color deconvo-
lution tool using positive (U6 probe without counterstain) and nega-
tive (scramble probe with methyl green counterstain) control slides,
respectively. The average optical densities of each stain in the red,
blue, and green channels were then entered into the colocalization
algorithm. The program creates a digital map of the slide made up of
3 colors: blue for positive staining, green for nuclear counterstaining,
and aqua for colocalized blue and green staining. This digital map
was visually checked against the original image to ensure accuracy.
The program outputs the area of each color as a percentage of all 3
colors. Positive staining was calculated by adding the percentages of
blue and aqua (% positive staining).
Luciferase Assay
We used the Cignal SMAD Reporter kit (SABiosciences, Fred-
erick, MD) to investigate the effects of miR-200b on the TGF-β-
induced signal transduction pathway.24 The construct encodes the fire-
fly luciferase reporter gene under the control of a minimal (m)CMV
promoter and tandem repeats of the SMAD transcriptional response
element. The assay was carried out according to the manufacturer’s
instructions. Cultured human bronchial epithelial cells, BEAS-2B
(ATCC, Manassas, VA), were cotransfected with 0.5 μg/mL of the
SMAD reporter construct and 0.01 μg/mL of LNA-oligonucleotide—
inhibitor, mimic, or control (Exiqon)—using the X-tremeGENE
siRNA Transfection Reagent (Roche). After 48 hours, luciferase ac-
tivity was measured with a Dual-Luciferase Reporter Assay System
(Promega, Madison, WI).
Western Blots
BEAS-2B cells were transfected with 0.01 μg/mL of LNA-
oligonucleotides. After 48 hours, the cells were washed and protein
extracts were prepared in lysis buffer: 10 mM Tris-HCl (pH 6.8),
5 μM β-glycerophosphate, 20 μM EDTA, 5% SDS, a protease in-
hibitor cocktail tablet, and phosphatase inhibitors (1 mM sodium
orthovanadate, 2 mM EDTA, 10 mM sodium pyrophosphate, 30 mM
sodium chloride). The supernatant protein concentration was deter-
mined using RC DC Protein Assay (Bio-Rad, Hercules, CA). Fifteen
micrograms of total protein was reduced with mercaptoethanol, size
fractionated with SDS-PAGE and transferred to a nitrocellulose mem-
brane (Bio-Rad). Specific proteins were detected with the following
antibodies: anti-SMAD2/3 (1:750) (Cell Signaling, Danvers, MA),
anti-phospho-SMAD2 (1:750) (Cell Signaling), anti-ZEB2 (1:500)
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-GAPDH (1:10000)
(Abcam). Primary antibodies were detected using HRP-conjugated
goat–anti-rabbit antibody (1:7000) (Bio-Rad) and HRP-conjugated
goat–anti-mouse antibody (1:7000) (Bio-Rad). Exposed films were
scanned and band densities were obtained after background subtrac-
tion using ImageJ software in a blinded fashion. Band densities were
normalized against the corresponding GAPDH values.
Statistical Analysis
All quantitative data are presented as mean ± standard error
of the mean or median and interquartile range (IQR) where appropri-
ate. Statistical analyses were performed using the statistical software
SigmaStat (version 3.5; Systat Software Inc). Statistical comparisons
were performed using the unpaired Student t test and nonparametric
Mann-Whitney U test where appropriate. Paired analysis was per-
formed using a Wilcoxon signed rank test. Differences were consid-
ered significant at P < 0.05.
RESULTS
miR-200b and miR-10a Expression Are Increased
in Fetal Hypoplastic CDH Lungs
The expression profile of the 319 human miRNAs tested is
shown as a heat map in Figure E1 of the online data supplement
(available at http://links.lww.com/SLA/A738). Two miRNAs, miR-
200b and miR-10a, were more abundant in prenatal hypoplastic CDH
lungs compared to age-matched normal control lungs (P < 0.01) (Fig.
1A). Both miR-200b and miR-10a had an approximately threefold
greater expression in CDH lungs compared to age-matched control
lungs (Fig. 1B). Four other miRNAs—miR-27a, miR-195, let-7a,
and miR-1—were tested on the basis of near significant differences
in the microarray analysis (Fig. E1, available at http://links.lww.com/
SLA/A738). None of these had a statistically significant difference in
expression in CDH lungs compared to control lungs using RT-qPCR
(results not shown).
Tracheal Fluid: Responders Have Higher Expression
of miR-200 Than Nonresponders After FETO
On the basis of these observations, we focused on validating
and further exploring the expression of the miR-200 family (miR-
200a, miR-200b, miR-200c, miR-141, and miR-429) and miR-10a
in tracheal and amniotic fluid samples of CDH patients at baseline
(plug) as well as following forced lung growth by FETO (unplug). Re-
sponders (ie, with measurable lung growth and eventually surviving)
to FETO had increased expression of the miR-200 family in their tra-
cheal fluid. Expression of miR-200 was higher after FETO (unplug)
in responders compared to nonresponders (Figs. 2A–E). However,
their baseline expression was not different. Conversely, tracheal fluid
miR-10a expression was lower in responders than in nonresponders
at baseline (plug). After FETO (unplug), the expression of miR-10a
increased in responders but remained unchanged in nonresponders
(Fig. 2F).
Expression of miR-200 Family and miR-10a
in Amniotic Fluid Decreases After FETO
After FETO (unplug), the amniotic fluid levels of the investi-
gated miRNAs did not mirror what was observed in the tracheal fluid.
The amniotic fluid levels were overall lower. Because the lungs con-
tribute largely to the amniotic content in the third trimester and were
occluded during FETO, this was anticipated.25 The expression pro-
files of all investigated microRNAs exhibited a similar trend: FETO
responders had significantly higher expression than nonresponders
(Fig. 3). More specifically, expression of miR-200a and miR-200c
significantly decreased after FETO (unplug) (Figs. 3A and C). Ex-
pression of miR-200a, miR-200c, miR-141, and miR-10a was higher
in amniotic fluid of survivors than in nonsurvivors after FETO (un-
plug) (Figs. 3A, C, D, and F).
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FIGURE 1. Upregulation of miR-200b and miR-10a in prenatal lungs in CDH. Total RNA was extracted from 3 CDH cases and
3 age-matched controls (Ctrl). A, Heat map representation of normalized microarray data (log 2 scale). Of the 319 miRNAs
tested, miR-200b and miR-10a were overexpressed in hypoplastic lungs (P < 0.01). B, Real-time PCR confirmed overexpression
of miR-200b and miR-10a in CDH (∗P < 0.05). miRNA expression is normalized relative to SNORD38B (U38B).
A Good Pulmonary Response After FETO Also Alters
Pulmonary Vascular Reactivity to Oxygen
The median relative increase in O/E LHR in fetuses surviv-
ing after birth was significantly higher than in nonresponders [161.7
(IQR: 252.4–140.8) vs 29.8 (IQR: 10.4–50.2); P < 0.0001] (Table 2).
Vascular reactivity could be assessed in 4 of 10 poor responders and 6
of 11 good responders. In fetuses with poor response after FETO, we
did not observe a change in median deltaPI [−2.0% (IQR: −10.3 to
31.0) vs 13.6% (IQR: 1.3–28.2); P = 0.63]. In contrast in fetuses with
a good response, median deltaPI increased significantly after FETO
[4.6% (IQR: −1.3 to 11.9) vs 23.0% (IQR: 3.4–39.8); P = 0.03].
Expression of miR-200b Is Higher in the Distal Part
of Postnatal Hypoplastic Lungs
We performed in situ hybridization to determine miR-200b ex-
pression in a separate set of postnatal lung sections. Hypoplastic CDH
lungs were characterized by increased miR-200b expression, partic-
ularly in the terminal saccules and alveoli (Fig. 4A). We used image
analysis software to generate color-coded maps and quantify the area
of positive staining for each lung section. Using this method, neona-
tal hypoplastic CDH lungs displayed increased miR-200b expression
compared to age-matched control lungs (Fig. 4B).
In situ hybridization for miR-200b produced a highly specific
staining pattern in normal neonatal lungs. Bronchial epithelial cells
were intensely positive for miR-200b (Fig. 4C, thick black arrow). In
contrast, parabronchial smooth muscle cells were predominantly neg-
ative for miR-200b (Fig. 4C, thick white arrow). Terminal saccules
contained a mixed population of positive (alveolar type II cells) and
negative-staining cells. In blood vessels, endothelial cells (inner layer)
were positive for miR-200b (Fig. 4C, black arrowhead). Perivascu-
lar smooth muscle cells, on the other hand, were negative (Fig. 4C,
white arrowhead). Mesothelial cells of the pleura were positive for
miR-200b (results not shown).
TGF-β2, a miR-200b Target Gene, Expression Is
Decreased in Hypoplastic CDH Lungs
Others have identified components of the TGF-β-induced sig-
nal transduction pathway as the major targets of the miR-200 family.26
We used immunohistochemistry to assess TGF-β2 expression in post-
natal lung tissues. The cellular distribution of TGF-β2 was very sim-
ilar to miR-200b, that is, expressed in bronchial epithelial cells and
vascular endothelial cells, but absent from parabronchial and perivas-
cular smooth muscle cells. CDH lungs displayed decreased TGF-β2
expression in terminal saccules compared to age-matched control
lungs (Fig. 5A).
miR-200b Downregulates TGF-β Signaling in Human
Bronchial Epithelial Cells
Downstream effects of TGF-β-induced signal transduction
are initiated through SMAD2/3 phosphorylation and its subsequent
nuclear translocation.27 We used a luciferase bioluminescent assay
to measure SMAD-induced gene expression and the impact of
changing miR-200b expression in cultures of human bronchial ep-
ithelial cells. In a pilot experiment measuring miR-200b expression
in different cell lines relevant to lung, we demonstrated that these
cells exhibit abundant miR-200b expression (results not shown). In
absence of exogenous TGF-β, bronchial epithelial cells displayed
very little SMAD-dependent luciferase activity. This low baseline
activity did not change when miR-200b mimics were added to the
culture medium. On the contrary, inhibitors of miR-200b increased
SMAD-luciferase activity by several orders of magnitude (Fig. 5B).
Collectively, these data suggest that basal TGF-β-induced signaling
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FIGURE 2. miR-200 family members and miR-10a expression analysis in tracheal fluid samples of surviving and nonsurviving
patients with CDH undergoing FETO. Expression levels of miR-200a (A), miR-200b (B), miR-200c (C), miR-141 (D), miR-429 (E),
and miR-10a (F) in tracheal fluid samples. Expression levels of these microRNAs were normalized to cel-miR-39. Statistical analysis
was performed using the Mann-Whitney U test for independent comparisons between surviving and non-surviving patients and
a Wilcoxon signed-rank test for paired comparisons between plug and unplug, ∗P < 0.05; †P < 0.01; ‡P < 0.001.
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FIGURE 3. miR-200 family members and miR-10a expression analysis in amniotic fluid samples of surviving and nonsurviving
patients with CDH undergoing FETO. Amniotic fluid levels of miR-200a (A), miR-200b (B), miR-200c (C), miR-141 (D), miR-429
(E), and miR-10a (F). Expression levels of these microRNAs were normalized to cel-miR-39. Statistical analysis was performed
using the Mann-Whitney U test, for independent comparisons between surviving and non-surviving patients and a Wilcoxon
signed-rank test for paired comparisons between plug and unplug, ∗P < 0.05; †P < 0.01.
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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FIGURE 4. In situ hybridization for miR-200b (blue stain) in postnatal lung (methyl green counterstain, 200× magnification).
A, Terminal saccules of control vs CDH lungs (color-coded maps: blue = positive staining, green = negative staining, aqua =
colocalized positive and negative staining). B, Area of positive staining (% blue +% aqua) was calculated for each lung section
(∗P < 0.05). C, miR-200b expression in normal postnatal lung. In bronchioles, miR-200b is expressed in epithelial cells (black
thick arrow), but is absent from parabronchial smooth muscle cells (white thick arrow). In blood vessels, miR-200b is expressed in
endothelial cells (black arrowhead) but is absent from the surrounding smooth muscle cells (white arrowhead). Terminal saccules
contain a mixed population of miR-200b-positive (black thin arrow) and miR-200b-negative (white thin arrow) cells.
is tempered by steady state levels of miR-200b, and that reducing
miR-200b is permissive for TGF-β-induced signaling.
To clarify mechanisms that might underpin altered basal
SMAD-mediated responses, we next performed Western blotting
using antibodies against total SMAD2/3 and phospho-SMAD2/3
(p-SMAD). Addition of miR-200b inhibitors or mimics to cultures
of bronchial epithelial cells resulted in a nearly twofold increase or
decrease, respectively, in p-SMAD levels; however, total SMAD2/3
abundance was unaffected (Fig. 5C). ZEB2 is a downstream transcrip-
tional repressor in the TGF-β/SMAD signal transduction pathway and
a putative target of miR-200b based on sequence complementarity.27
Addition of miR-200b inhibitors or mimics to cultures of bronchial
epithelial cells resulted in a nearly twofold increase or decrease, re-
spectively, in ZEB2 levels (Fig. 5C).
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FIGURE 5. miR-200b Target Gene Expression. A, Immunohistochemistry for TGF-β2 (brown stain) in control vs CDH postnatal
lungs (hematoxylin counterstain, 200× magnification). B, SMAD-luciferase reporter assay in cultures of bronchial epithelial cells.
Luciferase activity was measured after a 48-hour incubation with miR-200b inhibitor, mimic, or control oligonucleotide. C,
Immunoblotting for ZEB2 and phospho-SMAD (p-SMAD). Bronchial epithelial cells were incubated for 48 hours with miR-200b
inhibitor, mimic, or control oligonucleotide (∗P < 0.05).
DISCUSSION
The lack of success in identifying a pure genetic cause for CDH
prompted us to investigate the role of epigenetics and more in partic-
ular microRNAs. Our study is the first to demonstrate altered miRNA
expression in human congenital lung disease. Homogenates of hy-
poplastic lungs from CDH fetuses display miR-200b and miR-10a
overexpression. We then selected tracheal and amniotic fluid samples
from fetuses with appropriate or insufficient lung growth after fe-
tal surgery. Responders could be discriminated from nonresponders
by a significantly higher miR-200 expression in their tracheal fluid,
suggesting that stimulated lung development is associated with an
increase in miR-200 expression. Upregulation of miR-200b persists
in terminal saccules of CDH patients and is associated with decreased
TGF-β2 expression. In vitro, miR-200b inhibits TGF-β/SMAD sig-
naling in bronchial epithelial cells.
Using in situ hybridization, we determined that miR-200b
is overexpressed in the terminal saccules of postnatal CDH lungs
compared to age-matched controls. miR-200b is a member of the
miR-200 family, including also miR-200a, miR-200c, miR-141,
and miR-429.26,28–32 These miRNAs have similar sequences and
are transcribed in 2 clusters: miR-200b, miR-200a, and miR-429
share a common transcription start site on chromosome 1, whereas
miR-200c and miR-141 are transcribed as a single unit from
chromosome 12. There is increasing evidence that members of
the miR-200 family play a role in cancer. Several studies have
demonstrated that miR-200 expression is upregulated in epithelial
tissues, where they contribute to the epithelial cell phenotype by
inhibiting mesenchymal gene expression.29 We observed strong
miR-200b expression in bronchial and alveolar epithelial cells. In
contrast, parabronchial smooth muscle cells, which are differentiated
mesenchymal cells, were negative for miR-200b. Mesothelial and
endothelial cells were also positive for miR-200b. We have previously
demonstrated that hypoplastic CDH lungs are characterized by a
disturbed epithelial/fibroblast cell ratio in favor of fibroblasts.23
The miR-200 family functions by inhibiting several genes in-
volved in the TGF-β/SMAD signaling pathway.26,33 Increased TGF-β
activity enhances miR-200 expression as part of a negative feed-
back loop.34 Others have previously demonstrated in the surgical
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sheep model of CDH that FETO increased TGF-β2 expression in hy-
poplastic lungs.35 In addition, increased TGF-β expression has been
observed in hypoplastic lungs in the nitrofen-induced rat model of
CDH.36–38 Here, we observed increased miR-200 expression in pre-
natal and postnatal lung tissues in CDH and tracheal fluid samples of
CDH patients responding to FETO. Our data suggest that the increase
in miR-200 might result from an inherent increased TGF-β expres-
sion in hypoplastic lungs. In addition, FETO can increase miR-200b
expression even further in lungs responding to mechanical stretch
via upregulation of TGF-β expression in these lungs. The primary
insult leading to CDH and pulmonary hypoplasia occurs very early
in gestation when a diagnosis cannot be made yet.39,40 Because of
the unavailability of human fetal tissues during these early stages of
lung development, we were unable to investigate miRNA or TGF-β
expression at the time of the primary insult. In postnatal lung tis-
sues of CDH cases, we observed decreased TGF-β2 expression, par-
ticularly in the terminal saccules. During fetal lung development,
endogenous TGF-β blocks hormone-induced type II epithelial cell
differentiation.41 Decreased TGF-β activity in late stages of lung
development might explain why human cases of CDH display nor-
mal surfactant maturation.42,43 In addition, exogenous surfactant has
been demonstrated to be of no benefit in the treatment of pulmonary
hypoplasia associated with CDH.44,45
We established the inhibitory effect of miR-200b on TGF-β/
SMAD signaling in human bronchial epithelial cells. Given their
epithelial phenotype, these cells displayed a very low level of intrin-
sic SMAD2/3 activity. miR-200b inhibition significantly enhanced
SMAD2/3 phosphorylation, suggesting that in bronchial epithelial
cells, miR-200b functions by suppressing endogenous TGF-β activ-
ity. Both increased and decreased TGF-β signaling can lead to abnor-
mal lung development.46–48 Our results suggest that miR-200b plays
an important role in normal lung development by closely regulating
TGF-β signaling.
Extracellular microRNAs have recently emerged as potential
biomarkers because they have been shown to be associated with
various pathological conditions including cancer. Biomarkers have
also successfully been used to stratify therapy and/or to evaluate re-
sponse to therapy. Both miR-200 and miR-10a have earlier served as
biomarkers in some conditions. Most of these studies have focused on
their role in cancer progression. Increased serum miR-200c expres-
sion is associated with colorectal cancer progression and metastasis49
and gastric cancer.50 In contrast, decreased miR-200a expression is
associated with poor prognosis and recurrence in ovarian cancer.51
The role of miR-10a as a biomarker is less well established. A recent
study showed overexpression of miR-10a in human pancreatic can-
cer cells.52 Furthermore, a combination of miR-10a and miR-200b
has recently been reported to be a valuable microRNA signature for
metastatic medullary thyroid carcinoma53 and bladder cancer.54 We
have shown that tracheal fluid expression of miR-200 and miR-10a
can serve as a marker of response to FETO. Although FETO decreased
amniotic miRNA expression, survivors could be distinguished by
higher expression of miR-200a, miR-200c, miR-141, and miR-10a.
Considering our study limitations, we are aware that this study
has a relatively small sample size, no detailed phenotypic informa-
tion on the termination of pregnancy patients, a narrow window of
gestational age in the FETO group and most importantly, no control
amniotic or tracheal fluids. For obvious reasons, it would be unethical
to try and obtain tracheal fluid samples from control patients. The
first experiment was carefully planned to include only prenatal lungs
for identification of potential microRNAs as etiological factors of
pulmonary hypoplasia in CDH. CDH is typically diagnosed at sec-
ond trimester ultrasound55 and therefore, our 3 pairs of prenatal CDH
and control lungs (22–25 weeks of gestation) form a unique homoge-
nous set of severely hypoplastic lungs, which were not exposed to
confounding pre- or postnatal factors directly interfering with lung
development (steroids, ventilation, etc). These lungs were obtained
from terminations of pregnancies for medical reasons and processed
for research purposes within 1 hour of termination. In addition, the
tracheal and amniotic fluid samples were carefully collected as part
of a systematic collection of biofluids in a very well characterized
homogenous group of patients undergoing FETO.
CONCLUSIONS
We are the first to report altered microRNA expression in clin-
ical cases with abnormal lung development due to severe isolated
CDH. Future studies should reveal if manipulating miR-200 and
miR-10a expression improves the natural course in CDH patients
and their abnormal lung development.
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